Skip to main content

Advertisement

SpringerLink
Log in

Effects of Treatment of Ovariectomized Adult Rhesus Monkeys with Parathyroid Hormone 1-84 for 16 Months on Trabecular and Cortical Bone Structure and Biomechanical Properties of the Proximal Femur

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Treatment of monkeys and humans with parathyroid hormone (PTH) 1-84 stimulates skeletal remodeling, which increases trabecular (Tb) bone mineral density (BMD) but decreases cortical (Ct) BMD at locations where these bone types predominate. We report the effects of daily PTH treatment (5, 10, or 25 μg/kg) of ovariectomized (OVX) rhesus monkeys for 16 months on bone structure and biomechanical properties at the proximal femur, a mixed trabecular and cortical bone site. PTH reversed the OVX-induced decrease in BMD measured by dual-energy X-ray absorptiometry at the proximal femur, femoral neck, and distal femur. Peripheral quantitative computed tomography confirmed a significant decrease in Ct.BMD and an increase in Tb.BMD at the total proximal femur and at the proximal and distal femoral metaphyses. The decrease in Ct.BMD resulted primarily from increased area because cortical bone mineral content was unaffected by PTH. Histomorphometry revealed that PTH significantly increased the trabecular bone formation rate (BFR) as well as trabecular bone volume and number. PTH did not affect periosteal or haversian BFR at the femoral neck, but cortical porosity was increased slightly. PTH had no effects on stiffness or peak load measured using a shear test, whereas work-to-failure, the energy required to fracture, was increased significantly. Thus, PTH treatment induced changes in trabecular and cortical bone at the proximal femur that were similar to those occurring at sites where these bone types predominate. Together, the changes had no effect on stiffness or peak load but increased the energy required to break the proximal femur, thereby making it more resistant to fracture.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Mosekilde L, Søgaard CH, Danielsen CC, Tørring O (1991) The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129:421–428

    Article  PubMed  CAS  Google Scholar 

  2. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR (1993) The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577–1584

    Article  PubMed  CAS  Google Scholar 

  3. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525

    Article  PubMed  CAS  Google Scholar 

  4. Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Barbier JR, Isaacs RJ, Andreassen TT (2001) The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats. Calcif Tissue Int 68:95–101

    Article  PubMed  CAS  Google Scholar 

  5. Fox J, Miller MA, Newman MK, Metcalfe AF, Turner CH, Recker RR, Smith SY (2006) Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength. Calcif Tissue Int 79:262–272

    Article  PubMed  CAS  Google Scholar 

  6. Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L (1999) Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 25:301–309

    Article  PubMed  CAS  Google Scholar 

  7. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY (2007) Treatment of skeletally-mature ovariectomized rhesus monkeys with parathyroid hormone 1-84 for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260–273

    Article  PubMed  CAS  Google Scholar 

  8. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633

    CAS  Google Scholar 

  9. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220

    Article  PubMed  CAS  Google Scholar 

  10. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575

    Article  PubMed  CAS  Google Scholar 

  11. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM (2001) Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157–165

    Article  PubMed  CAS  Google Scholar 

  12. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  13. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146:326–339

    PubMed  Google Scholar 

  14. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535

    Article  PubMed  CAS  Google Scholar 

  15. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768

    Article  PubMed  CAS  Google Scholar 

  16. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543

    Article  PubMed  CAS  Google Scholar 

  17. Bogado CE, Zanchetta JR, Gordon CL, Bouxsein ML, Mathisen AL, Fox J, Morris S (2006) Treatment of postmenopausal osteoporotic women with parathyroid hormone (1-84) for 18 months decreases BMD but does not affect indices of bone strength at the distal radius. J Bone Miner Res 21(suppl 1):S112

    Google Scholar 

  18. Jerome CP, Turner CH, Lees CJ (1997) Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265–270

    Article  PubMed  CAS  Google Scholar 

  19. Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J (1998) Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13:1775–1782

    Article  PubMed  CAS  Google Scholar 

  20. Brommage R, Hotchkiss C, Lees CJ, Stancill MW, Hock JM, Jerome CP (1999) Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84:3757–3763

    Article  PubMed  CAS  Google Scholar 

  21. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R (2001) Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150–159

    Article  PubMed  CAS  Google Scholar 

  22. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY (2007) Effects of daily treatment with parathyroid hormone 1-84 on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. doi: http://dx.doi.org/10.1016/j.bone.2007.04.197

  23. Smith SY, Recker R, Kimmel DB, Akhter M, Metcalfe A, Dietrich J (1998) Efficacy of recombinant human parathyroid hormone (1-84) (rhPTH (1-84)) in ovariectomized rhesus monkeys. Bone 23:S633

    Google Scholar 

  24. FDA Guidance (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis, http://www.fda.gov/cder/guidance/osteo.pdf

  25. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595–610

    Article  PubMed  CAS  Google Scholar 

  26. Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97–104

    Article  PubMed  CAS  Google Scholar 

  27. Littell RC, Stroup WW, Freund RJ (2002) SAS for Linear Models, 4th ed. SAS Press, Cary, NC, pp 256–261

  28. Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005

    PubMed  CAS  Google Scholar 

  29. Miller MA, Chin J, Miller SC, Fox J (1998) Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23:257–266

    Article  PubMed  CAS  Google Scholar 

  30. Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau IA (2005) Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5:356–357

    PubMed  CAS  Google Scholar 

  31. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  PubMed  CAS  Google Scholar 

  32. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH (2004) Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623–629

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NPS Pharmaceuticals, 383 Colorow Drive, Salt Lake City, UT, 84108, USA

    J. Fox & M. A. Miller

  2. Osteoporosis Research Center, Creighton University, 601 North 30th Street, Omaha, NE, 68131, USA

    R. R. Recker

  3. Department Biomedical Engineering, Indiana University-Purdue University, 1120 South Drive, Indianapolis, IN, 46202, USA

    C. H. Turner

  4. Charles River Laboratories Preclinical Services Montréal, 22022 Transcanadienne, H9X 3R3, Senneville, Quebec, Canada

    S. Y. Smith

Authors
  1. J. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. R. Recker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. H. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Y. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Fox.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, J., Miller, M.A., Recker, R.R. et al. Effects of Treatment of Ovariectomized Adult Rhesus Monkeys with Parathyroid Hormone 1-84 for 16 Months on Trabecular and Cortical Bone Structure and Biomechanical Properties of the Proximal Femur. Calcif Tissue Int 81, 53–63 (2007). https://doi.org/10.1007/s00223-007-9036-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-007-9036-y

Keywords

Search

Navigation